Pierre Jean Lamy

Summary

Publications

  1. ncbi [Iron metabolism in breast cancer: knowledge and future]
    Anna Durigova
    Service d Oncologie Medicale, CRLC Val d Aurelle Paul Lamarque, Montpellier, France
    Ann Biol Clin (Paris) 70:387-96. 2012
  2. pmc SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases
    Jocelyne Jacquemier
    Institut Paoli Calmettes, Biopathology Department, 232 Bd Ste Marguerite, 13009, Marseille, France
    BMC Cancer 13:351. 2013
  3. pmc Worldwide variations in EGFR somatic mutations: a challenge for personalized medicine
    Pierre Jean Lamy
    Laboratoire de Biologie Spécialisée et Oncogénétique, CRLC Val d Aurelle Paul Lamarque, France
    Diagn Pathol 7:13. 2012
  4. doi Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy
    William Jacot
    Departement d Oncologie Medicale, CRLC Val d Aurelle Paul Lamarque, 208, rue des Apothicaires, 34298 Montpellier, France
    Breast Cancer Res Treat 134:709-17. 2012
  5. doi The HER2 amplicon in breast cancer: Topoisomerase IIA and beyond
    William Jacot
    Service d Oncologie Medicale, CRLC Val d Aurelle Paul Lamarque, Montpellier, F 34298, France
    Biochim Biophys Acta 1836:146-57. 2013
  6. pmc Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles
    William Jacot
    Departement d Oncologie Medicale, CRLC Val d Aurelle Paul Lamarque, 208, rue des Apothicaires, F 34298, France
    Breast Cancer Res 13:R133. 2011

Collaborators

  • William Jacot
  • Evelyne Lopez-Crapez
  • Maryse Fiche
  • Frederic Bibeau
  • Jocelyne Jacquemier
  • Anna Durigova
  • Cécile Blanc Fournier
  • Alexander Valent
  • Jacqueline Lehmann-Che
  • Benjamin Esterni
  • Ludovic Lacroix
  • Jean Marc Guinebretiere
  • Philippe Bertheau
  • Patricia De Cremoux
  • Michèle Legrain
  • Anne Vincent Salomon
  • Marie Joelle Mozziconacci
  • Luc Xerri
  • Martine Antoine
  • Aline Seaume
  • Sophie Krieger
  • Ivan Bieche
  • Frederique Penault-Llorca
  • Gaetan MacGrogan
  • Marie Christine Mathieu
  • Marie Pierre Chenard
  • Laurent Arnould
  • Sophie Vacher
  • Francoise Revillion
  • Sarab Lizard
  • Delphine Loussouarn
  • Magali Lacroix Triki
  • Frederique Spyratos
  • Yves Marie Robin
  • Isabelle Hostein
  • Geneviève Portefaix
  • Sylvie Roques
  • Stéphane Pouderoux
  • Frédéric Montels

Detail Information

Publications6

  1. ncbi [Iron metabolism in breast cancer: knowledge and future]
    Anna Durigova
    Service d Oncologie Medicale, CRLC Val d Aurelle Paul Lamarque, Montpellier, France
    Ann Biol Clin (Paris) 70:387-96. 2012
    ..This is an innovative approach that has emerged for treating a cancer which, despite advances in treatment and the emergence of targeted therapies, remains the leading cause of cancer death in women...
  2. pmc SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases
    Jocelyne Jacquemier
    Institut Paoli Calmettes, Biopathology Department, 232 Bd Ste Marguerite, 13009, Marseille, France
    BMC Cancer 13:351. 2013
    ....
  3. pmc Worldwide variations in EGFR somatic mutations: a challenge for personalized medicine
    Pierre Jean Lamy
    Laboratoire de Biologie Spécialisée et Oncogénétique, CRLC Val d Aurelle Paul Lamarque, France
    Diagn Pathol 7:13. 2012
    ..Like in lung cancer, the EGFR mutation profiles seem to be related to the ethnical origin of patients. This is an important point that should be considered when developing anti-EGFR therapies...
  4. doi Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy
    William Jacot
    Departement d Oncologie Medicale, CRLC Val d Aurelle Paul Lamarque, 208, rue des Apothicaires, 34298 Montpellier, France
    Breast Cancer Res Treat 134:709-17. 2012
    ..Further studies are needed to determine how drugs modulate this regulatory mechanism to preserve bone homeostasis in patients with breast cancer...
  5. doi The HER2 amplicon in breast cancer: Topoisomerase IIA and beyond
    William Jacot
    Service d Oncologie Medicale, CRLC Val d Aurelle Paul Lamarque, Montpellier, F 34298, France
    Biochim Biophys Acta 1836:146-57. 2013
    ..In addition it will discuss the clinical and biological implications of the amplification of ten other genes at this locus (MED1, STARD3, GRB7, THRA, RARA, IGFPB4, CCR7, KRT20, KRT19 and GAST) in breast cancer...
  6. pmc Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles
    William Jacot
    Departement d Oncologie Medicale, CRLC Val d Aurelle Paul Lamarque, 208, rue des Apothicaires, F 34298, France
    Breast Cancer Res 13:R133. 2011
    ..Because variations in the frequency of EGFR-activating mutations in East Asians and other patients with lung cancer have been described, we evaluated the EGFR mutational profile in tumour samples from European patients with TNBC...